Portola Pharmaceuticals Inc  

(Public, NASDAQ:PTLA)   Watch this stock  
Find more results forPTLA
45.85
-0.08 (-0.17%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.17 - 46.12
52 week 23.34 - 49.37
Open 46.12
Vol / Avg. 339,272.00/449,736.00
Mkt cap 2,390.61M
P/E     -
Div/yield     -
EPS -3.39
Shares 52.05M
Beta     -
Inst. own 96%
Aug 3, 2015
Q2 2015 Portola Pharmaceuticals Inc Earnings Release (Estimated) - 4:00p.m. GMT-4 - Add to calendar
Jun 16, 2015
Portola Pharmaceuticals Inc Annual Shareholders Meeting
Jun 10, 2015
Portola Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
May 12, 2015
Portola Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Q1 2015 Portola Pharmaceuticals Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 Portola Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1988.68% -1424.67%
Operating margin -1971.34% -1429.26%
EBITD margin - -1413.24%
Return on average assets -41.69% -36.95%
Return on average equity -49.08% -42.58%
Employees 99 -
CDP Score - -

Address

270 East Grand Avenue, Suite 22
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2446864 (Phone)
+1-650-2467376 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.

Officers and directors

Charles J. Homcy M.D. Co-Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Hollings C. Renton III Independent Co-Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
William Lis Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Mardi C. Dier Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
John T. Curnutte M.D. Ph.D. Executive Vice President - Research & Development
Age: 63
Bio & Compensation  - Reuters
Tao Fu Executive Vice President, Chief Commercial and Business officer
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 57
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
John H. Johnson Director
Age: 57
Bio & Compensation  - Reuters
Jeffrey W. Bird M.D., Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters